Literature DB >> 26949003

FDA-Approved Anti-Obesity Drugs in the United States.

Homayoun L Daneschvar1, Mark D Aronson2, Gerald W Smetana2.   

Abstract

Obesity is a growing health problem in our society and its treatment has been challenging. In recent decades, several anti-obesity drugs have been withdrawn from the market because of reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. The majority of these medications are taken orally, and only one is administered subcutaneously. In this article, we review the efficacy, adverse effects, and mechanism of action of all 5 FDA-approved drugs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Anti-obesity drugs; Obesity; Weight loss; Weight loss drugs

Mesh:

Substances:

Year:  2016        PMID: 26949003     DOI: 10.1016/j.amjmed.2016.02.009

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  33 in total

1.  Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.

Authors:  T Kaisho; H Nagai; T Asakawa; N Suzuki; H Fujita; K Matsumiya; N Nishizawa; Y Kanematsu-Yamaki; K Dote; J-I Sakamoto; T Asami; S Takekawa
Journal:  Int J Obes (Lond)       Date:  2017-07-31       Impact factor: 5.095

Review 2.  Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment.

Authors:  Hung Manh Phung; Dongyeop Jang; Tuy An Trinh; Donghun Lee; Quynh Nhu Nguyen; Chang-Eop Kim; Ki Sung Kang
Journal:  J Ginseng Res       Date:  2022-04-04       Impact factor: 5.735

3.  A bibliometric analysis of research on herbal medicine for obesity over the past 20 years.

Authors:  Yeonho Seo; Han-Song Park; Hyungsuk Kim; Koh-Woon Kim; Jae-Heung Cho; Won-Seok Chung; Mi-Yeon Song
Journal:  Medicine (Baltimore)       Date:  2022-06-10       Impact factor: 1.817

Review 4.  Oxytocin as a potential pharmacological tool to combat obesity.

Authors:  Pawel K Olszewski; Emily E Noble; Luis Paiva; Yoichi Ueta; James E Blevins
Journal:  J Neuroendocrinol       Date:  2022-02-22       Impact factor: 3.870

5.  US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity.

Authors:  G Gomez; F C Stanford
Journal:  Int J Obes (Lond)       Date:  2017-11-20       Impact factor: 5.095

Review 6.  Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.

Authors:  Sneha Singh; Maria L Ricardo-Silgado; Suzette J Bielinski; Andres Acosta
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 5.002

Review 7.  Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2016-11-29       Impact factor: 8.775

Review 8.  Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges.

Authors:  Hak Yung Ng
Journal:  Adolesc Health Med Ther       Date:  2016-12-16

9.  Phytohemagglutinin ameliorates HFD-induced obesity by increasing energy expenditure.

Authors:  Yunxia Zhang; Jin Li; Hui-Hui Wang; Jiao Li; Yue Yu; Bo Li; Li Huang; Changjing Wu; Xiaomeng Liu
Journal:  J Mol Endocrinol       Date:  2021-06-17       Impact factor: 5.098

10.  The Root of Atractylodes macrocephala Koidzumi Prevents Obesity and Glucose Intolerance and Increases Energy Metabolism in Mice.

Authors:  Mi Young Song; Soo-Kyoung Lim; Jing-Hua Wang; Hojun Kim
Journal:  Int J Mol Sci       Date:  2018-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.